Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance)
      QxMD      Google Scholar   
Citation:
Clin Trials vol 16 (2) 165-175
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Book Volume:
8
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, HHS-N261201000063C, U10CA180791, U10CA180838, U10CA180867  
Corr. Author:
 
Authors:
                 
Networks:
CA136, LAPS-MA036, LAPS-NC007, LAPS-NY016   
Study
NCCTG-N1048
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2/3
Keywords:
Locally advanced rectal cancer, neoadjuvant FOLFOX, total mesorectal excision, combined modality treatment, chemoradiation, patient-reported outcomes and symptom burden using PRO-CTCAE, central radiology review of pelvic MRIs, phase II/III hybrid design, co-primary endpoints, pragmatic design elements in cooperative group cancer clinical trials